Development of a new methodology to determine size differences of nanoparticles with nanoparticle tracking analysis

Extracellular Vesicles
Nanomedicine
Viruses
/References

Pellequer, Yann, Gilbert Zanetta, Jean-Michel Rebibou, Isabelle Severin, Marie-Christine Chagnon, Gernot Zissel, Fabrice Neiers, and Renaud Seigneuric. "Development of a new methodology to determine size differences of nanoparticles with nanoparticle tracking analysis." Applied Nanoscience (2021): 1-13.

The current frontiers in Biology thus in Medicine and Pharmacy are at the nanoscale. Indeed, this is the relevant scale for extracting or synthetizing, visualizing, counting, characterizing and/or modifying nanoparticles. Nanoparticles are highly diverse including: extracellular vesicles (e.g.: exosomes), proteins, viruses and nanovectors or drug delivery systems for instance. To quantify the concentration of nano-sized objects, a growing number of size-tracking instruments is being developed. However, to date, the generated data is only used to provide a concentration measurement. The objective of this study was to determine which sizes of nanoparticles are statistically significant between 2 groups of samples. Using different samples (in silico data; calibrated beads; various biological samples), an approach that statistically compares 2 groups of samples was developed and validated. The proof of concept of the proposed approach was illustrated with applications in the field of Biology, Medicine and Pharmacy using liposomes and extracellular vesicles. For the first time to our knowledge, our results suggest that the presented approach enables comparing different groups of biological samples. It may be extended to situations such as batch 1 versus batch 2; healthy versus disease or non-treated versus treated.

View full article

Recent Publications

Cigarette smoke (CS) represents one of the most relevant environmental risk factors for several chronic pathologies. Tissue damage caused by CS exposure is mediated, at least in part, by oxidative stress induced by its toxic and pro-oxidant components. Evidence demonstrates that extracellular vesicles (EVs) released by various cell types exposed to CS extract (CSE) are characterized by altered biochemical cargo and gained pathological properties. In the present study, we evaluated the content of oxidized proteins and phospholipid fatty acid profiles of EVs released by human bronchial epithelial BEAS-2B cells treated with CSE. This specific molecular characterization has hitherto not been performed. After confirmation that CSE reduces viability of BEAS-2B cells and elevates intracellular ROS levels, in a dose-dependent manner, we demonstrated that 24 h exposure at 1% CSE, a concentration that only slight modifies cell viability but increases ROS levels, was able to increase carbonylated protein levels in cells and released EVs. The release of oxidatively modified proteins via EVs might represent a mechanism used by cells to remove toxic proteins in order to avoid their intracellular overloading. Moreover, 1% CSE induced only few changes in the fatty acid asset in BEAS-2B cell membrane phospholipids, whereas several rearrangements were observed in EVs released by CSE-treated cells. The impact of changes in acyl chain composition of CSE-EVs accounted for the increased saturation levels of phospholipids, a membrane parameter that might influence EV stability, uptake and, at least in part, EV-mediated biological effects. The present in vitro study adds new information concerning the biochemical composition of CSE-related EVs, useful to predict their biological effects on target cells. Furthermore, the information regarding the presence of oxidized proteins and the specific membrane features of CSE-related EVs can be useful to define the utilization of circulating EVs as marker for diagnosing of CS-induced lung damage and/or CS-related diseases.

2023